CTOs on the Move

Sanofi Genzyme

www.sanofigenzyme.com

 
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Pharmetics

Pharmetics is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orthobrain

At orthobrain®, we have reinvented the delivery of orthodontics, providing access to more people and providing dentists the opportunity to offer excellent orthodontic care to their patients. orthobrain`s consulting and education platform, powered by the expertise of Orthodontists, makes it faster, better, and easier than ever for general practitioners to deliver orthodontic care with confidence. With our system, your patients will obtain an Orthodontist-designed diagnosis, a step-by-step detailed treatment plan, and custom-made appliances from a trained dentist they already know and love - you! orthobrain makes it easy for you to start offering orthodontics in your practice immediately and transform your patients smiles for good.

Bridge Laboratories

Bridge Laboratories is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.

Gastro Health

We are a medical group of physicians and health professionals that specialize in gastrointestinal disorders, nutrition and digestive health. Our offices are conveniently located throughout South Florida, Orlando and Fort Myers.